The UC Davis Comprehensive Cancer Center, a consortium with Lawrence Livermore National Laboratories, is a matrix organization under the aegis of UC Davis Health and the University of California, Davis. Our members are organized into five programs, supported by eight shared resources and a developing immune monitoring resource.
It is the mission of the center to inspire and facilitate many of the University’s talented scientists and physicians to tackle cancer challenges. As a comprehensive center, our achievements in scientific research must move quickly into cancer clinics to benefit patients throughout our region and beyond.
Our research community
Center members are organized into programs, shared resources and innovation groups to transcend departmental affiliations and to be transdisciplinary, translational and transformative. Our purpose is the generation and dissemination of new knowledge. Our vision is “Breaking Barriers to Beat Cancer.” We accomplish much of this work through our Cancer Center members.
Cancer Center membership is open to all UC Davis faculty and Lawrence Livermore National Laboratory researchers who have a focused interest in cancer and/or related disciplines; and a commitment to contribute to the cancer center mission. Members must have an academic appointment. Exceptions to this policy are considered on a case-by-case basis.
To be eligible for full membership, ONE of the following requirements must be met:
- Is principal investigator (PI) or co-principal investigator of a current cancer research grant from NCI or an NCI-approved peer-review agency or organization and has current (within the last two years) cancer-related peer-reviewed publications — https://cancercenters.cancer.gov/documents/PeerReviewFundingOrganizations508C.pdf
- Conducts clinical research as a PI and accrues a minimum of six patients per year to therapeutic clinical trials
- Holds a cancer center leadership position(s) in a shared resource and/or a leadership position in a cancer-relevant organization on a national or international level
To be eligible for associate membership, ONE of the following requirements must be met:
- Has submitted a competitive cancer-related grant application within the last three years and is an author of a peer-reviewed cancer-related publication
- Is a newly recruited faculty member or an established investigator new to cancer research, who is applying for independent competitive cancer-related funding
- Contributes to clinical cancer research as a co-investigator of an investigator-initiated trial and/or accrues a minimum of three patients per year to a therapeutic clinical trial
Membership will be reviewed and renewed every two years based on membership criteria. Active members in good standing who find themselves in transition without current funding or pending publications will be issued a grace period (of up to two years) to meet membership requirements. After two years, members without funding, publications or cancer-relevant research will have to reapply for membership once eligibility requirements are met.
Members are expected to contribute to the UC Davis Comprehensive Cancer Center through the following:
- Support the cancer center’s mission to generate discoveries to increase understanding of the biology of cancer, to improve the prevention, diagnosis and treatment of cancer for populations in its diverse catchment area and beyond, and to prepare trainees as leaders in cancer care and research.
- Secure cancer-relevant funding as a principal investigator or develop investigator-initiated trials and accrue patients to the cancer center’s clinical trials
- Publish cancer research articles in peer-reviewed journals and list the cancer center as an affiliation on publications
- Attend program meetings (min. 50% attendance, at least two meetings per year)
- Attend and participate in seminars, symposias and meetings sponsored by the cancer center
- Annually (and as needed) provide the cancer center with a current NIH biosketch with recent publications and a statement of “Other Support”
- Provide information as requested for the preparation of the competitive renewal of the Cancer Center Support Grant (CCSG) and the annual non-compete progress reports
- Demonstrate commitment to collaborate with other members; and promote interdisciplinary, multi-investigator research efforts
- Participate in research-related activities at the center including peer review assignments and occasional fundraising activities, participate in planning and evaluation, and in cancer center committees to enhance research
- Maintain web biography
- Focus on translational cancer research regardless of perspective (e.g., basic scientist, clinical researcher, etc.)
- Participate in cancer-related mentoring activities and training programs
- Acknowledge the use of cancer center facilities, shared resources, space or assistance from the Cancer Center Support Grant.
- Acknowledge each publication, press release, or other document about research supported by the CCSG by including an acknowledgement, such as:
“Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA093373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
- Eligible for priority access and subsidized rates to the Cancer Center shared resources (rate structures will vary by shared resource)
- NOTE: Associate members with plans to perform highly impactful cancer-focused research — particularly junior faculty who have not yet obtained extramural cancer funding — can qualify for a discount rate (equivalent to the rate for full members) from a CCSG Shared Resource, but only with the express approval of the shared resource director after review of the associate member's cancer-focused research plan.
- Eligible for Cancer Center Support Grant Developmental Awards
- Eligible for philanthropic funds directed towards cancer research (subject to availability)
- Assistance with pre-award grant management of cancer-related proposals, including biostatistical support for proposal development.
- Pre-award administrative support for the execution of major, collaborative funding proposals such as P01 and U01 proposals, T32 training grants, or SPORES; these proposals are characterized by substantial, transdisciplinary participation of researchers
- Eligible to apply for start-up packages, bridge funding, or CCSG-supported leadership positions
- Ability to collaborate with scientists and clinicians with related scientific interests through innovation groups
- Access to online membership portal, which includes information for the 5 Research Programs, new research initiatives, grant opportunities, shared resources and collaboration requests
- Eligible for intramural funds provided by the center
Complete the membership application form and all required attachments. Incomplete applications will be returned for completion before review.
Membership applications will be processed on the first business day of each month.
Each application will be reviewed by the respective program leaders and approved by cancer center leadership. Members will be notified via email on the outcome of their application review.
Membership will be reviewed and renewed every two years based on membership criteria. During the period of preparation for competitive renewal of National Cancer Institute designation, members will have their membership status reviewed for reappointment.
Reappointment review will evaluate activities associated with membership objectives. In particular, collaborative activities with members of the center’s scientific programs, attendance at membership meetings sponsored by programs or the center, participation in cancer center research efforts, leadership in significant cancer-related organizations, participation in peer-review study sections, or other demonstrations of interaction with the cancer center program will be considered. As a consequence of review, members may have their categorical membership changed or terminated if a strong cancer focus is not evident.